Latin American Journal of Pharmacy 2023-05-18T10:52:36+00:00 Latin American Journal of Pharmacy Open Journal Systems <p align="justify"><strong><em>Latin American Journal of Pharmacy</em> (formerly <em>Acta Farmacutica Bonaerense</em>) ISSN 0326 2383</strong> is the scientific journal of the College of Pharmacists of Buenos Aires Province, Argentina. The journal publishes research reports in the form of original articles or short communications on most aspects of pharmaceutical sciences, with strong emphasis on originality and scientific quality. More specifically, but not exclusively, the journal publishes mainly reports in medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery, pharmaceutical technology and biotechnology, pharmaceutical care, and clinical drug evaluation. Reviews or mini-reviews are not encouraged, but experimental articles are privileged. Articles reporting the isolation of secondary metabolites of plants will be only considered if biological and toxicological assays are included. In general, reports on biological activities of crude extracts are not considered for publication unless any bioactive compound is isolated and identified. Contributions reporting unexceptional and predictable bioactivity (for instance, antioxidant activity of extracts or antimicrobial activity of essential oils) are not normally considered for publication.<br /><br />Articles are indexed and abstracted in Chemical Abstracts Service, International Pharmaceutical Abstracts Service, BioScience Information Service (Biological Abstracts), Periodica (Index of Latin American Scientific Journals), International Pharmaceutical Technology &amp; Product Manufacture Abstracts, Referativnyi Zhurnal (Institut of Scientific Information, Russian Academy of Sciences), EMBASE/Excerpta Medica, LILACS (Latin American and Caribbean Health Sciences Literature) and LATINDEX. The journal was awarded in 1986 and 2000 with APTA-Antonio Rizzuto prize (scientific journals category) and in 2002 was qualified as scientifical journal level one (excellent) by the Argentine Center of Scientific and Technological and Information (CAICYT-.CONICET) within the LATINDEX Project, integrantes the Common Core of Argentinian Scientific Journals and has been proclaimed as a journal of provincial interest by the Honorable Deputy Chamber of Buenos Aires Province, Argentina. <br />From 2017, <em>Lat. Am. J. Pharm.</em> publishes twelve issues per year</p> Nanodiamond as a drug delivery vehicle and gene therapy tool 2023-05-18T10:52:36+00:00 Moataz Dowaidar s@s.b <p>Using nanodiamond (ND) as an effective medication delivery vehicle offers tremendous optimism and anticipation. This topic has received considerable attention despite being a relatively young field of nanodiamond research. Great efforts have concentrated on material development, surface conjugation, and cytotoxicity research, all aimed at using ND for bio/medical applications, notably in bioimaging and more effective drug administration. ND-mediated medication delivery has made considerable progress in the past decade. Different techniques of conjugating different ND surface medicines to ND-X complexes target different cancers or tumors; extremely favorable results were obtained from cell and animal models. While this affects the field of nanomedicine, it is not yet apparent whether and when clinical translations will occur. Many issues persist. Materials are the first issue. The Nanodiamond originates from numerous manufacturing firms in varied sizes and shapes, created with different techniques with different surfaces and impurities. It exhibits highly diverse surface characteristics and cytotoxicity. All applications must take care of the surface, conjugation and toxicity tests. It's time-consuming and cost-consuming, and outcomes vary. These add to the cost of developing an animal and clinical complex. To establish requirements for nanodiamond materials appropriate for medical use, characterization or regulation is essential. This helps to scale up and decrease manufacturing costs, and also to converge on the outcome for applications. Moreover, while numerous imaging and therapeutic applications have been made using ND to create ND-X for drug administration, the route to clinics seems hard. As a result, the majority of cellular and animal research is a short-term observation with no long-term safety evaluation.The maximum allowable dose of ND and medication inside the animal appears to be an important parameter for clinical translation; the outcome (or fate) and biodistribution of nanodiamond retention in the animal's body requires long-term evidence to support ND's safe therapeutic use.ND's future focus will be on bio/medical applications. Many concepts were accomplished at the animal model level. This feat will surely draw attention from pharmaceutical, medical, and material producers. Clinical translations are expected in the future as interdisciplinary efforts are incorporated into the development of ND-mediated drug delivery.Nanodiamond particle aggregation and well-dispersed nanodiamonds for bio/medical applications. Studies of numerous animal models of the biodistribution of ND throughout the animal's body and its long-term destiny in the organs. Controlled drug delivery through ND-mediated, pH-sensitive animal model delivery. Nanodiamond conjugation methods use covalent bonding or physical adsorption for distribution to optimize efficacy and decrease the adverse effects of anticancer medicines. Recently, advancements in ND-drugs have targeted various animal models of malignancies.of drugs supplied to target locations are more efficient, and drug retention in tumors is longer than a pure drug. Promising clinical translations.</p> 2023-05-01T00:00:00+00:00 Copyright (c) 2023